image credit: Freepik

Bayer unit takes heart failure gene therapy into phase 2

January 12, 2024

The new GenePHIT study is enrolling patients with non-ischaemic cardiomyopathy and New York Heart Association (NYHA) class III heart failure who have been medically stable for at least 4 weeks.

People with this stage of CHF will have a marked reduction in their ability to carry out exercise and will be comfortable only at rest. Up to 150 patients will be randomised in the study to receive either a single intracoronary infusion of the gene therapy, given at two dose levels, or a matched placebo.

Read More on Pharmaphorum